Sign Up Today and Learn More About CHARM Therapeutics Stock
Invest in or calculate the value of your shares in CHARM Therapeutics or other pre-IPO companies through EquityZen's platform.
CHARM Therapeutics Stock
Charm Therapeutics designs and develops small-molecule therapeutics that target the interaction between menin and the KMT2A protein.
About CHARM Therapeutics Stock
Founded
2021
Industries
Software, Artificial Intelligence, Data and Analytics
CHARM Therapeutics Press Mentions
Stay in the know about the latest news on CHARM Therapeutics
Occam Global Strengthens Life Science Leadership with Transformative 2025
prweb • Dec 11, 2025
CHARM Therapeutics advances CHM-029, a next-generation menin inhibitor designed to overcome resistance mutations, as its first clinical candidate for acute myeloid leukaemia (AML)
biospace • Nov 14, 2025
CHARM Therapeutics advances CHM-029, a next-generation menin inhibitor designed to overcome resistance mutations, as its first clinical candidate for acute myeloid leukaemia (AML)
globenewswire • Nov 14, 2025
2025 Cambridge deals pass $9.25bn as AstraZeneca and Honeywell step on the gas
businessweekly • Oct 25, 2025
Cambridge life sciences fundraisings pass $700m as Q3 maintains strong momentum
businessweekly • Oct 17, 2025
CHARM Therapeutics Management
Leadership team at CHARM Therapeutics
Co-Founder, CEO, and Board Member
Laksh Aithani
Scientific Co-Founder
David Baker
Join now and verify your accreditation status to gain access to:
- CHARM Therapeutics Current Valuation
- CHARM Therapeutics Stock Price
- CHARM Therapeutics Management
- Available deals in CHARM Therapeutics and all other companies with relevant Deal Offering documents
- EquityZen's proprietary data and insights, which may include
- CHARM Therapeutics Cap Table and Funding History by Share Class and Liquidity Preferences
- CHARM Therapeutics Revenue and Financials
- CHARM Therapeutics Highlights
- CHARM Therapeutics Business Model
- CHARM Therapeutics Risk Factors
- CHARM Therapeutics Research Report from SACRA Research
Trading CHARM Therapeutics Stock
How to invest in CHARM Therapeutics stock?
Accredited investors can buy pre-IPO stock in companies like CHARM Therapeutics through EquityZen funds. These investments are made available by existing CHARM Therapeutics shareholders who sell their shares on our platform. Typically, these are early employees who need to fund a life event – house, education, etc. Accredited investors are then offered the opportunity to invest in this stock through a fund, like those used by hedge funds serving large investors. While not without risk, investing in private companies can help investors reach goals of portfolio diversification, access to potential growth and high potential return. Learn more about our Guided Investment process for buying Pre-IPO Shares.
How to sell CHARM Therapeutics stock?
Shareholders can sell their CHARM Therapeutics stock through EquityZen's private company marketplace. EquityZen's network includes over 440K accredited investors interested in buying private company stock. Learn more about the Shareholder liquidity process.
If I invest, how do I exit my investment?
There are two ways to exit your private company investment on EquityZen's marketplace. The first is if the company has an exit event like an IPO, merger or acquisition. In that case, we will distribute the shares and/or cash to you directly. The second way is through an Express Deal on EquityZen, if eligible. An Express Deal allows you to sell your allocation of private shares in a given private company to another investor on EquityZen's marketplace. See more information on Express Deals and pre-IPO exit information.
Why choose EquityZen?
Since 2013, the EquityZen marketplace has made it easy to buy and sell shares in private companies. EquityZen brings together investors and shareholders, providing liquidity to early shareholders and private market access to accredited investors. With low investment minimums through our funds and with more than 52K private placements completed across 450+ companies, EquityZen leads the way in delivering "Private Markets for the Public."